Iovance Biotherapeutics Inc (LTS:0JDK)
$ 11.29 0.295 (2.68%) Market Cap: 3.48 Bil Enterprise Value: 3.15 Bil PE Ratio: 0 PB Ratio: 4.43 GF Score: 30/100

Q4 2023 Iovance Biotherapeutics Inc Earnings Call Transcript

Feb 28, 2024 / 09:30PM GMT
Release Date Price: $17.33 (+0.17%)
Operator

Welcome to the Iovance Biotherapeutics conference call to discuss the full-year 2023 results and recent corporate updates. My name is Kevin, and I'll be your operator for today's call. (Operator Instructions). Please note that this conference is being recorded.

I will now turn the call over to Sara Pellegrino, Senior Vice President, Investor Relations and Corporate Communications, Iovance. Sara, you may begin.

Sara Pellegrino
Iovance Biotherapeutics Inc - Senior Vice President, Investor Relations and Corporate Communications

Thank you, operator. Good afternoon and thank you for joining our conference call and webcast to discuss full-year 2023 results and recent corporate updates. Dr. Fred Vogt, our Interim President and Chief Executive Officer, will provide a brief introduction. Jim Ziegler, EVP Commercial, will highlight our initial insights for the US commercial launch of Amtagvi following the recent Food and Drug Administration or FDA approval in advanced melanoma. Igor Bilinsky, Chief Operating Officer, will highlight commercial manufacturing and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot